Northwest Biotherapeutics announced on October 26, 2026 that it has expanded its technical team in the United States while simultaneously eliminating select positions, resulting in a net increase in US headcount with operating costs remaining in the same range as before the changes.

Key Highlights

  • Net US headcount increase: The company disclosed that new hires produce a net increase in US personnel, but with "operating costs remaining in the same range as before these changes."
  • QA and Regulatory Affairs Manager hired: The new manager previously served as Director of DC Operations, Center for Immunotherapy at Roswell Park Cancer Center.
  • Director of Information Technologies hired: The new director previously served as Director of Technology at Team Logic IT, the company's own external IT service provider.
  • Manager of Investor Relations added: The filing describes him as a former institutional fund manager with over 30 years of experience at top tier asset managers, long-only funds, and hedge funds.
  • One US position terminated so far: The company stated it has terminated one position among its US employees and may eliminate additional positions as priorities evolve.
  • Two priority operational areas: The company is prioritizing scale-up of US and UK manufacturing capacity and preparations for clinical trials in cancers beyond brain cancer.

Northwest Biotherapeutics Restructures US Team Around Manufacturing Scale-Up and Trial Expansion

According to the filing, Northwest Biotherapeutics (OTCQB:NWBO) is expanding its US technical workforce while reducing positions it considers non-essential to its current priorities. The company described two core focus areas driving the staffing changes: scaling up production capacity, including restarting US manufacturing as additional or backup capacity alongside its UK operations, and preparing for clinical trials in cancer indications beyond brain cancer.

The company disclosed three specific new hires. The newly appointed QA and Regulatory Affairs Manager, who came from Roswell Park Cancer Center, will lead quality assurance functions for cGMP manufacturing and oversee regulatory compliance in US cGMP operations, including regulatory training of production personnel. The new Director of Information Technologies, hired directly from Team Logic IT, is described as assisting the company's Chief Information Officer in scaling operations, including the handling, distribution, and tracking of the company's personalized cancer vaccine products. The new Manager of Investor Relations will work alongside the company's existing Head of Investor Relations on investor and shareholder communications.

On reductions, the company stated it has so far terminated one US position and indicated it will continue reviewing its personnel mix, with the possibility of eliminating additional roles whose skill sets are "not necessary for the Company's evolving priorities." The filing also noted a similar review process is underway in the UK, involving both adding personnel with expertise in priority operations and reducing others. The company provided no specific figures for total current headcount or the number of positions under consideration for elimination.

What Was Disclosed

Northwest Biotherapeutics disclosed a net expansion of its US technical team through three named new hires in quality assurance, information technology, and investor relations, offset by at least one terminated position, with overall US operating costs described as unchanged.